Rucaparib is an Orally Active PARP Inhibitor for Prostate Cancer Research
Ovarian cancer (OC) is the eighth most common neoplasia in women, and the fifth leading cause of cancer-related deaths. Due to a lack of early stage detection, about 70% of…
Ovarian cancer (OC) is the eighth most common neoplasia in women, and the fifth leading cause of cancer-related deaths. Due to a lack of early stage detection, about 70% of…